Staphylococcal manipulation of host immune responses

Vilasack Thammavongsa[*], **Hwan Keun Kim**, **Dominique Missiakas**, and **Olaf Schneewind**

Department of Microbiology, University of Chicago, 920 East 58th Street, Chicago, Illinois 60637, USA

Abstract

Staphylococcus aureus, a bacterial commensal of the human nares and skin, is a frequent cause of soft tissue and bloodstream infections. A hallmark of staphylococcal infections is their frequent recurrence, even when treated with antibiotics and surgical intervention, which demonstrates the bacterium's ability to manipulate innate and adaptive immune responses. In this Review, we highlight how *S. aureus* virulence factors inhibit complement activation, block and destroy phagocytic cells and modify host B and T cell responses, and we discuss how these insights might be useful for the development of novel therapies against infections with antibiotic resistant strains such as methicillin-resistant *S. aureus*.

Approximately 30% of the human population is continuously colonized with *Staphylococcus aureus*, whereas some individuals are hosts for intermittent colonization[1]. *S. aureus* typically resides in the nares but is also found on the skin and in the gastrointestinal tract. Although colonization is not a prerequisite for staphylococcal disease, colonized individuals more frequently acquire infections[1]. Skin and soft tissue infections (SSTIs) are the most frequent disease form of *S. aureus*, and these infections can progress to bacteremia and invasive disease, i.e. bloodstream infection, endocarditis or sepsis[2]. In addition, *S. aureus* can cause pneumonia, osteomyelitis, infectious arthritis, abscesses in many organ tissues and infections of surgical wounds or prosthetic materials[2]. Annual attack rates for *S. aureus* disease range between 1-3% and vary with age, ethnicity and geographical location of human populations[2]. At elevated risk for staphylococcal infection are low-birth-weight infants, children, elderly and patients with indwelling catheters, endotracheal intubation,

medical implantation of foreign bodies, trauma, surgical procedures, hemodialysis, diabetes and immunosuppressive or cancer therapy[2]. A key feature of *S. aureus* disease is its recurrence, which for SSTI and bloodstream infections, occurs for 8-33% of cases[3]. Prior disease does not elicit protection against subsequent *S. aureus* infection[2].

Neutrophils play a central part in protecting humans against *S. aureus* infection. Staphylococcal entry and replication in host tissues leads to the release of bacterial products (formyl-peptides, lipoproteins or peptidoglycan) and to damaged tissues that produce inflammatory signals, i.e. chemoattractants and cytokines[4]. Immune cells perceive staphylococcal products via Toll-like receptors and G-protein coupled receptors, while cytokines activate cognate immune receptors. Neutrophils answer this call, extravasate from blood vessels, and migrate towards the site of infection to phagocytose and kill bacteria or to immobilize and damage the pathogen through NETosis – the release of neutrophil extracellular traps (NETs) comprising DNA and antimicrobial peptides[4]. The importance of neutrophils in controlling *S. aureus* infection has been documented through the study of immune defects. Mutations in genes encoding NADPH oxidase, the enzyme generating bactericidal superoxide in phagocytes, cause chronic granulomatous disease (CGD), which is associated with defects in phagocytic killing of *S. aureus* and frequent infection[5]. Individuals with inborn errors of STAT1/STAT3 signalling of immune cells are perturbed for IL-17 cytokine pathways, which diminishes mucocutaneous immunity and promotes *S. aureus* infection[6]. IL-17-dependent T cell signalling is a key activator of neutrophils and of anti-staphylococcal defenses[7]. Finally, cancer patients with diminished blood neutrophil counts are highly susceptible to *S. aureus* infection[8].

Nevertheless, the vast majority of *S. aureus* disease occurs in immune-competent individuals without defects in phagocyte function. To achieve this, *S. aureus* deploys an arsenal of immune evasive strategies that together prevent phagocytosis and killing by neutrophils. Further, the pathogen's ability to cause recurrent disease implies the presence of mechanisms that effectively block the development of adaptive immune responses. Here, we review recent work on the immune evasive attributes of *S. aureus*, including the subversion of the innate and adaptive immune systems and the killing of immune cells, along with epidemiological features of the corresponding genes. We also discuss how the characterization of bacterial immune evasive factors can have translational impact in the therapy of autoimmune diseases or the development of vaccines and immunotherapeutics against *S. aureus* infection.

Subversion of innate immune responses

Neutrophil extravasation and chemotaxis

Pro-inflammatory signals promote neutrophil adhesion and extravasation across capillary endothelia, relying on reciprocal interactions between endothelial receptors (P-/E-selectins, ICAM-1, hyaluronan) and ligands on neutrophil surfaces (PSGL-1, LFA-1, Mac-1, CD44)[9]. Although neutrophils seek to migrate towards bacterial invaders, *S. aureus* can interfere with neutrophil extravasation and chemotaxis through the secretion of staphylococcal superantigen-like proteins (SSLs), phenol-soluble modulins (PSMs), chemotaxis inhibitory

protein of *S. aureus* (CHIPS), formyl peptide receptor-like 1 inhibitor (FLIPr) and its homologue FLIPr-like (FLIPr-L).

SSLs are a family of secreted proteins with structural homology to staphylococcal superantigens[10-12]. The *ssl* genes are arranged as tandem repeats in genomic island α (GIα, *ssl1-11*) and in the immune evasion cluster 2 (IEC2, *ssl12-14*) on the bacterial chromosome[13]. GIα-encoded *ssl* genes vary between lineages as does the coding sequence of individual *ssl* genes; the number of different alleles ranges from 1 to 13 and most alleles are uniquely associated with specific *S. aureus* lineages[13]. *ssl1*, *ssl2*, *ssl3*, *ssl11*, *ssl12*, *ssl13* and *ssl14* are found in all *S. aureus* isolates[13] (Box 1). Purified, recombinant SSL5 and SSL11 bind PSGL-1 on leukocytes and, when assayed*in vitro*, interfere with the binding of neutrophils to P-selectin and neutrophil adhesion/rolling[14,15](Fig. 1a). SSL5 also interferes with chemokine- and anaphylatoxin-mediated activation of neutrophils by binding to the glycosylated N-termini of G protein coupled receptors[14,16]. Moreover, SSL5 has been shown to activate platelets and support their adhesion involving platelet surface receptors GPIbα and GPVI[17,18]. Intravenous administration of SSL5 caused intravascular platelet-rich thrombi and increased bleeding of C57Bl/6 mice[19]. Other work demonstrated SSL5-mediated inactivation of leukocyte matrix metalloprotease 9[20]. The affinity of SSL5 for different host factors is mediated via its glycan binding pocket, an attribute that is shared by other members of the SSL family[21]. SSL3 binds to TLR2 and blocks immune cell recognition of staphylococcal lipoproteins and peptidoglycan via TLR1/2 and TLR2/6 heterodimers[22], and SSL10 blocks CXCR4-mediated responses on lymphocytes, interfering with the chemoattraction of neutrophils[4] (Fig. 1a). Recent work suggests that SElX, a staphylococcal enterotoxin (superantigen)-like protein, also binds glycosylated PSGL-1 and that SSL6 binds to CD47 (integrin associated protein), a common receptor on most host tissues that promotes migration, anti-phagocytosis and proliferation[23]. Thus, SSLs presumably associate with a wide spectrum of glycoproteins on leukocytes and/or platelets to implement immune evasive attributes. Most SSLs display species specificity for human but not animal host factors and SSL-mediated contributions towards *S. aureus* pathogenesis cannot be measured in animal experiments. *S. aureus* also inhibits leukocyte migration via the extracellular adherence protein (Eap). Eap is composed of four β-grasp-like domains and associates with ICAM-1 to inhibit leukocyte migration[24]. The *eap* gene is located in the *eap*/*hlb* locus, the attachment site for *hlb*-converting phages carrying the IEC1 gene cluster[13] (Box 1).

PSMs are a family of short formyl-peptides that are secreted via an ABC transporter and interfere with the physiological functions of immune cells, specifically neutrophils[25]. PSMα1-4 and PSMβ1-2, whether formylated or not, activate formyl-peptide receptor 2 (FPR2) on human and mouse neutrophils and stimulate cytokine release[26]. Of note, PSMα1-4 and PSMβ1-2 are neutralized by binding to serum lipoproteins and reactive oxygen species of activated neutrophils are reported to neutralize PSM signalling[27]. Recent work demonstrated that PSMα3N22Y, a variant with diminished FPR2-binding activity that is secreted by the clonal complex 30 (CC30) MRSA lineage, is associated with diminished FPR2 signalling and diminished cytotoxicity, while enhancing bacterial replication and the establishment of abscess lesions in renal tissues[28]. The activation of FPRs via the formyl

moiety of PSMs and via their direct binding to FPR2 stimulates chemotaxis. Thus, a key attribute of formylated PSMs seems to be the stimulation of neutrophil chemotaxis via FPRs.

S. aureus also counters neutrophil chemotaxis, which occurs via the secretion of CHIPS, FLIPr and FLIPr-L[4] (Fig. 1a). CHIPS is encoded by the *chp* gene in IEC1, which is carried on the *hlb*-converting phages[29]. *chp* is found in most human *S. aureus* isolates but not in livestock associated strains[13]. Secreted CHIPS binds to human FPR1 and human C5aR, the complement receptor of neutrophils, but not to mouse FPR1 or C5aR[30,31]. FLIPr and FLIPr-L are encoded by genes in the IEC2 locus; at least 9 different alleles are known for these genes, which are found in many, but not all, human *S. aureus* isolates[13] (Box 1). FLIPr-L inhibits FPR1 signalling, whereas FLIPr and FLIPr-L bind to FPR2 and inhibit its receptor signalling function[32,33]. Finally, staphopain (ScpA), a secreted cysteine protease cleaves CXCR2 chemokines to block neutrophil migration towards staphylococci[34] (Fig. 1a). The life-style of *S. aureus* - invasion of host tissues, replication in abscess lesions, and dissemination upon purulent drainage of lesions - requires recruitment of immune cells to the site of infection[35,36]. However, staphylococcal products manipulate infiltrating immune cells to limit their capacity for chemotaxis, phagocytosis and bacterial killing, thereby ensuring the successful outcome of infection.

Complement activation and phagocytosis

Complement, a key component of innate host defenses, is composed of >30 proteins with broad functions in host defense against microbes, inflammation, hemostasis and wound repair. Complement is activated via any one of three routes, the classical pathway (CP; antibody and C1q deposition on the staphylococcal surface), lectin pathway (LP; MBL/MASPs association with staphylococcal carbohydrates) and alternative pathway (AP; spontaneous breakdown of the complement protein C3 in serum), which converge in the assembly of C3 convertase (C4b2a for CP and LP and C3bBb for AP). C3 convertase cleaves C3 into C3a and C3b; C3b becomes covalently linked to the staphylococcal surface (opsonization) and C3a is released as a chemoattractant for phagocytes[37]. At high local concentrations of C3b, the C5 convertase cleaves C5 into C5a, another chemoattractant, and C5b, whose surface deposition promotes membrane attack complex (MAC) formation[37]. MAC is effective at killing Gram-negative bacteria; however, it is not effective for *S. aureus*, which has a thick peptidoglycan layer that prevents access to the bacterial membrane[38].

In addition to the thick peptidoglycan layer, many clinical *S. aureus* strains express genes for the production of one of two types of capsular polysaccharide, type 5 or type 8[39]. *In vitro* phagocytosis assays suggested that capsule expression protects staphylococci from neutrophil phagocytosis in the presence of opsonins and that capsule expression contributes to the pathogenesis of *S. aureus* infection in mice[39]. Capsule-induced protection from phagocytosis may be strain specific, as capsule mutations in other *S. aureus* isolates do not affect the pathogenesis of bloodstream infections in mice[36]. USA300, the current pandemic clone of community-acquired MRSA infections, carries a mutation that abrogates capsule expression[40] (Table 1).

S. aureus secretes several proteins that interfere with the deposition of complement on the bacterial surface (Fig. 1b). Aureolysin, a secreted Zn-dependent metalloprotease, cleaves C3 to generate functionally active C3a and C3b. Complement factors I (fI) and H (fH) degrade or bind C3b, which prevents its accumulation on the staphylococcal surface [41]. The aureolysin gene, *aur*, is polymorphic and specific alleles are associated with different *S. aureus* lineages. An *in vivo* phenotype for *S. aureus aur* mutants has not yet been described.

Staphylococcal complement inhibitor (SCIN) associates with and inhibits C3 convertase (C3bBb), thereby preventing the production of C3a, C3b and C5a and interfering with complement activation[42](Fig. 1b). The structural gene for SCIN, *scn*, is also located on *hlb*-converting phages together with *chp* and *sak* (staphylokinase, see below). Two polymorphic homologs of SCIN, designated SCIN-B and SCIN-C, are encoded by genes in the IEC2 locus. *scn* as well as *scnB*/*scnC* are found in many, but not all, human clinical isolates (Box 1); SCIN, SCIN-B and SCIN-C associate with C3 convertase from humans but not with that of other vertebrates[43].

The genes encoding extracellular fibrinogen-binding protein (Efb) and its homologue, extracellular complement-binding protein (Ecb), are also located on IEC2. Both Efb and Ecb bind C3d, a cleavage product of C3b that activates innate and adaptive responses by binding to complement receptor 2 (CR2), and inhibit C3bBb and the C5 convertases[43,44](Fig. 1b). Ecb associates with both fH and C3b to facilitate the complement inhibitory attributes of factor H[45]. Efb also binds fibrinogen and prevents fibrinogen interaction with αMβ2, an integrin on neutrophils that activates proinflammatory responses, as well as fibrinogen-mediated platelet activation[46,47]. Efb and Ecb inhibitory activities have been observed for human as well as mouse convertases and fibrinogen. In the mouse intravenous challenge model, the *S. aureus efb ecb* mutant displayed reduced time-to-death and increased survival as well as diminished abscess formation in organ tissues[48]. The *ecb* gene is found in all *S. aureus* genomes sequenced to date, whereas *efb* is found in many, but not all human clinical isolates[13].

SSLs also interfere with complement activation and phagocytosis. For example, SSL7 binds human IgA and complement C5, interfering with IgA binding to FcαRI binding and the production of C5a and the oxidative burst of phagocytes *in vitro*; the *in vivo* contributions of SSL7 towards *S. aureus* pathogenesis are not known[49]. SSL10 binds to human and non-human primate IgG1, but not to immunoglobulins of lower vertebrates, and inhibits IgG1 binding to Fcγ receptors and the *in vitro* phagocytosis of IgG1-opsonized bacteria by immune cells[50,51].

Staphylococcal binder of immunoglobulin (Sbi) is a secreted protein with two immunoglobulin binding domains (IgBDs; designated Sbi-I and Sbi-II), which are triple-helical bundles that associate with the Fcγ-domain of human and vertebrate immunoglobulin (Box 2). Sbi-I and Sbi-II interfere with C1q binding to immunoglobulin and block the classical complement pathway[52,53](Fig. 1b). The Sbi-III and Sbi-IV domains associate with C3 and factor H to form tripartite complexes that inhibit the alternative pathway[54,55] (Fig. 1b). The *sbi* gene is located in the *sbi/hlg* locus of the core genome of all isolates[13]. Staphylokinase forms enzymatically active complexes with plasminogen, cleaving fibrin,

defensins, human IgG, C3b and iC3b on bacterial surfaces, thereby blocking complement activation[56-58](Fig. 1b). Collagen adhesin (Cna), a surface protein expressed by some *S. aureus* isolates, binds C1q and interferes with CP activation, blocking the association between C1q and C1r[59].

Neutrophil-mediated killing

Once phagocytosed, staphylococci are exposed to a variety of toxic products that kill and degrade the engulfed bacteria: antimicrobial peptides, reactive nitrogen (NO), reactive oxygen species (ROS - hydrogen peroxide, superoxide, hydroxyl radicals), cell wall hydrolases, and proteolytic enzymes[4]. However, *S. aureus* has evolved a number of strategies to survive in this environment (Fig. 1c). Peptidoglycan acetylation (OatA), D-alanylation of teichoic acids (DltABCD), and lysyl- or alanyl-phosphatidylglycerol synthesis (MprF) provide for staphylococcal resistance against lysozyme- and antimicrobial-peptide mediated killing by blocking enzyme (lysozyme) or peptide binding to its envelope target[60-62]. Staphyloxanthin, a carotenoid pigment synthesized by all *S. aureus* isolates[63] provides resistance against hydrogen peroxide/hydroxyl radicals, the bactericidal compounds of neutrophils[64] (this is not the case for CC75 isolates but we consider these to belong to a separate species, *Staphylococcus argenteus* (Box 1)). Similarly, two superoxide dismutases (SodA and SodM), fulfill overlapping functions in eliminating neutrophil superoxide[65], whereas catalase (KatG) and alkylhydroperoxide reductase (AhpC) protect staphylococci against hydrogen peroxide[66].

In response to nitrosative stress, *S. aureus* expresses flavohemoglobin (Hmp), which detoxifies nitric oxide, and L-lactate dehydrogenase, which maintains redox-hemostasis and survival within neutrophils by producing L-lactate[67].In addition to its role in inhibiting complement activation, Eap and two structural homologs, EapH1 and EapH2 (which do not inhibit complement) promote *S. aureus* survival by inhibiting neutrophil serine proteases (elastase, cathepsin G and proteinase 3)[68]. In the intravenous mouse challenge model, the *S. aureus eap* mutant displays a moderate virulence defect[36], however the *eap eapH1 eapH2* mutant displays reduced bacterial load and increased mouse survival[68].

Staphylococcal killing of host cells

In addition to its ability to inhibit phagocyte-mediated killing, *S. aureus* also manipulates innate immune responses by inducing the killing of innate immune cells via PSMs and different toxins (Fig. 1d). The PSMα locus encodes *psmα1-4*, whereas PSMβ encodes *psmβ1* and *psmβ2*. *psmβ2* is found in only some, but not all *S. aureus* strains[13]. Peptides similar to PSMα1-4 and PSMβ1 are expressed by *Staphylococcus epidermidis*, a commensal of the human skin that cannot cause abscess lesions or bloodstream infections in immune competent individuals[25]. Mutations that delete *psmα1-4* and *psmβ1-2* interfere with *in vitro* biofilm formation of *S. aureus* mutants and with the expression of virulence factors, including α-hemolysin[25]. *S. aureus psmα1-4* mutants are attenuated in the mouse bloodstream infection model[69], a phenotype that may be due to defects in biofilm formation, virulence gene expression and/or contributions of PSMα1-4 towards lysis of immune cells, presumably via membrane insertion and pore formation[70].

β-barrel pore-forming toxins (β-PFT) are secreted as soluble monomers and, upon association with receptors on cell surfaces, assemble into multimeric pore structures, penetrating the lipid-bilayer to invoke alterations in the physiology of injured cells or their outright lysis[71]. α-hemolysin (Hla), the prototype β-PFT of *S. aureus*, is encoded by the *hla* gene, which is located within IEC2. Although conserved among all *S. aureus* isolates, some lineages of *S. aureus* carry a nonsense mutation that blocks *hla* expression[72]. Hla binds to its receptor, ADAM10, and assembles into a heptameric pore; through the metalloprotease activity of ADAM10, Hla modulates the function of immune cells, including neutrophils, or triggers lysis of epithelial cells[73,74]. *S. aureus hla* mutants display defects in disease severity in mouse models for lethal pneumonia, bacteremia and SSTI, albeit that *hla* is not required for the establishment of *S. aureus* abscess lesions[75-77]. Based on ADAM10 expression on the surface of myeloid cells, organ epithelia and the vascular endothelium, Hla causes a wide spectrum of global as well as organ-specific changes that affect physiological host responses to *S. aureus* infection[74].

Several other β-PFTs secreted by *S. aureus* are designated leukocidins (Fig. 1d). Following leukocidin association with receptors on myeloid cells and erythrocytes, these toxins assemble from two different subunits (F an S) into an octameric pore structure[78]. All *S. aureus* strains produce at least three leukocidins, HlgAB, HlgCB and LukAB (LukGH), whereas other strains may also secrete Panton-Valentine leucocidin (PVL) and LukED or LukMF[79] (Box 1). The genes encoding *lukAB* (*lukGH*) are located immediately adjacent to *hlb*, whereas those encoding γ-hemolysin (*hlgABC*) are part of the *sbi/hlg* locus. LukAB (LukGH) binds to the I domain of human, but not mouse, CD11b (integrin αM) on myeloid cells[80]. Purified LukAB (LukGH) can trigger human neutrophils to release NETs that, at least temporarily, ensnare staphylococci[81]. LukAB (LukGH) has also been reported to promote *S. aureus* escape from the phagosome of neutrophils[82]. Purified HlgAB γ-hemolysin, but not purified HlgCB γ-hemolysin, is able to lyse human and rabbit red blood cells [83]. HlgAB binds chemokine receptors CXCR1, CXCR2 and CCR2, whereas HlgCB utilizes complement receptors C5aR and C5L2 to associate with target cells[84]. Following staphylococcal inoculation into human blood, *hlgABC* is upregulated 34-145 fold[85] and the *S. aureus   hlgABC* mutant displays reduced survival, presumably because HlgAB and HlgCB promote release of iron-compounds from erythrocytes, thereby enabling bacterial acquisition of this essential nutrient[83]. Both purified HlgAB and HlgCB promote lysis of neutrophils, monocytes and macrophages from humans as well as non-human primates, and to a lesser degree rabbits and mice[83]. In a mouse intravenous challenge model, animals infected with a *S. aureus lukGH* (*lukAB*) mutant displayed increased time-to-death and survival. Using subcutaneous inoculation in mice or rabbits, the *S. aureus lukGH* (*lukAB*) mutant did not display defects in skin abscess formation[86]. The   *hlgAB* mutant displayed a virulence defect in the intraperitoneal challenge model in mice[84].

LukED is present in the GIβ locus of about 70% of clinical *S. aureus* isolates[13] (Box 1). Purified LukED triggers lysis of macrophages, dendritic cells and T lymphocytes from many different vertebrates, as the toxin binds to the chemokine receptors CCR5, CXCR1 and CXCR2[87,88]. For *S. aureus* Newman, which harbors GIβ, the   *lukED* mutation increased the time-to-death and survival of mice following intravenous challenge with mutant

staphylococci[89]. Panton-Valentine leukocidin, also designated PVL or LukPV, is secreted by *S. aureus* lysogenized with PVL bacteriophage[90]. PVL binds to the C5aR on neutrophils, monocytes and macrophages but its activity is restricted towards human and rabbit cells[9]. By virtue of binding C5aR, PVL not only exerts its lytic activity on target host cells but can also facilitate the priming of human PMNs by proinflammatory stimuli, for example formyl-peptides. Injection of purified recombinant PVL leads to increased immune cell recruitment and increased architectural destruction of the lung, owing to toxin-mediated recruitment and subsequent lysis of immune cells[9]. Only about 2% of *S. aureus* isolates secrete PVL, however community-acquired MRSA isolates frequently harbor PVL bacteriophage and PVL expression is also associated with necrotizing pneumonia[91]. *S. aureus lukPV* variants display defects in the pathogenesis of skin and soft tissue infections and lung infections in rabbits, but not in mice, which seems to be due to neutrophil-mediated inflammatory responses and tissue distruction[76,92]. *lukMF*, genes for another bacteriophage-encoded leucocidin, are found in *S. aureus* isolates associated with bovine mastitis[13].

Staphylococcal agglutination

Coagulation, the conversion of fibrinogen to a crosslinked fibrin meshwork by activated thrombin, is an innate defense of all vertebrates, which immobilizes microbial invaders and attracts immune cells for phagocytic clearance of bacteria. Therefore, every successful bacterial pathogen must evolve mechanisms for escape from fibrin entrapment and subsequent phagocytosis by infiltrating immune cells. A hallmark of all *S. aureus* isolates is the secretion of two coagulases, coagulase (Coa) and von Willebrand Factor-binding protein (vWbp)[93]. Coa and vWbp associate with prothrombin, a zymogen, to generate enzymatically active staphylothrombin, which cleaves the A and B peptides of fibrinogen to generate fibrin fibrils[94](Fig. 2). As staphylothrombin does not cleave other substrates of thrombin, it avoids the activation of clotting and inflammatory factors that ordinarily accompany fibrin polymerization[95]. Staphylothrombin activity is not subject to feedback inhibition through host antithrombin. However, staphylothrombin is blocked by dabigatran and other direct thrombin inhibitors of the same family[96]. The staphylothrombin-generated fibrin meshwork protects *S. aureus* from phagocytes and contributes to the formation of staphylococcal abscess lesions and lethal bacteraemia in mice[97]. Activation of prothrombin is mediated by the N-terminal D1-D2 domain of Coa and is blocked by specific antibodies, which provide protection from *S. aureus* bloodstream infection in the mouse model[98]. Perhaps owing to purifying selection, *coa* is one of the most variable genes in the core genome of *S. aureus* with >50% sequence variation in the coding sequence for its D1-D2 domains and 14 distinct isoforms (Table 1)[93]. vWbp also has a conserved D1-D2 domain for association with prothrombin, but this complex generates fibrin at a reduced rate and contributes to abscess formation without affecting staphylococcal escape from phagocytosis[99]. The gene encoding vWbp, *vwb,* displays limited sequence variability[98].

S. aureus agglutinates with coagulase-derived fibrin fibrils, which requires clumping factor A (ClfA), a glycosylated, sortase-anchored surface protein whose immunoglobulin-like domains bind to the C-terminal end of the γ-chain in fibrinogen/fibrin (D domain)[96,100,101](Fig. 2). Thus, ClfA acts synergistically with Coa/vWbp in protecting

staphylococci from opsonophagocytic killing and *clfA* mutants display defects in the pathogenesis of lethal bloodstream infections in mice[96].

Four other sortase-anchored surface proteins use their immunoglobulin-like domains to bind fibrinogen/fibrin: ClfB (α-chain), fibronectin binding protein A (FnBPA) and B (FnBPB, C-terminal end of γ-chain), and bone sialoprotein binding protein (Bbp/SdrE isoform, α-chain)[102](Fig. 2). These surface proteins display functional redundancy for the *S. aureus* agglutination pathway and contribute to the pathogenesis of bloodstream infections[103].

Purified, recombinant SSL10 has also been reported to bind human fibrinogen and fibronectin as well as porcine prothrombin and factor Xa[51]. The association of SSL10 with prothrombin and Xa occurs via the Gla (γ-carboxylic acid) domain and interferes with calcium-activated blood clotting but not with staphylothrombin (coagulase)-mediated fibrin formation[51] (Fig. 2). *ssl7* and *ssl10* are not found in all *S. aureus* isolates[13].

Staphylokinase activates human, but not murine, plasminogen and may solubilize coagulase-induced fibrin deposits, thereby aiding *S. aureus* in generating purulent lesions for dissemination to new hosts (Fig. 1b). Of note, binding of surface proteins by fibrinogen/fibrin deposits has also been reported to influence staphylococcal interference with platelet aggregation and innate immune functions[104,105]. In addition to their role in binding to fibrin/fibrinogen, some surface proteins have been reported to bind additional host ligands, at least *in vitro*. Binding to these additional host ligands, which include complement factor I (by the surface protein ClfA), fibronectin (by the surface proteins FnBPA and FnBPB), keratin 10 (by the surface protein ClfB) and loricrin (by the surface protein ClfB), may contribute to staphylococcal immune evasion, invasion of host cells or colonization of squamous epithelia[102]. *fnbpA* and *fnbpB*, which are components of the *S. aureus* core genome, display sequence polymorphisms and seven isotypes with discrete antigenicity have been described[106] (Box 1).

Adenosine/deoxyadenosine signalling and NETosis

Adenosine is a potent mediator of immune responses and, under physiological conditions, is synthesized following hypoxia, exposure to reactive oxygen species (ROS) and cell lysis associated with tissue damage. Adenosine elicits its biological effects by binding to one or more of four G protein coupled receptors[107], A1 A2A, A2B and A3. Adenosine receptor interaction triggers anti-inflammatory signalling cascades that inhibit platelet aggregation, neutrophil superoxide burst, neutrophil degranulation, T cell activation and release of the cytokines IL-1α and IL-10[108]. *S. aureus* increases the concentrations of extracellular adenosine during infection by expressing AdsA, a sortase-anchored protein that catalyses the dephosphorylation of adenosine mono-, di- and triphosphates[109](Fig. 3a). Both *ex vivo* and during mouse infection, the *adsA* mutation increases killing of staphylococci by blood neutrophils, while decreasing extracellular adenosine[109]. Thus, AdsA-mediated synthesis of adenosine promotes survival of *S. aureus* within neutrophils, presumably by inhibiting superoxide burst and/or degranulation[109]. Further, adenosine decreases MHC-II expression in macrophages and dendritic cells and dampens IL-12 production, a pivotal stimulus for Th1-type immune responses[107]. Staphylococcal enhancement of adenosine production may

therefore interfere with T cell effector mechanisms and adaptive immune responses in infected hosts[109].

AdsA activity also modulates immune responses following the degradation of NETs. During bloodstream infection in mice, *S. aureus* disseminates to many different organ tissues to establish abscess lesions. These lesions are composed of a bacterial nidus, designated as the staphylococcal abscess community (SAC), encased within a pseudocapsule of fibrin deposits, and surrounded by layers of immune cells[97]. In spite of large numbers of infiltrated neutrophils, mice are unable to eliminate staphylococci from abscess lesions and eventually succumb to persistent infection[36]. Although neutrophils use NETosis to entangle staphylococci, NETs are degraded by staphylococcal nuclease (Nuc) and thereby fail to exert bactericidal activities[110](Fig. 3b). Nuclease digestion of NETs releases 5' and 3' monophosphate nucleotides that are converted by AdsA into deoxyadenosine (dAdo)[111](Fig. 3b). dAdo production triggers caspase-3 induced apoptosis of macrophages and prevents phagocyte entry into the SAC, the core of staphylococcal abscess lesions, thereby promoting bacterial survival within the lesion[111].

Manipulation of adaptive immune responses

B cell responses

S. aureus is capable of manipulating B cell survival and function, especially via the activity of SpA, which is a sortase-anchored surface protein with high affinity for vertebrate immunoglobulin, including human IgA, IgD, IgG1-4, IgM and IgE[112]. SpA is initially deposited in the staphylococcal envelope and subsequently released by cell wall hydrolases (LytM)[113]. *spa* is expressed by all clinical *S. aureus* isolates; the immunoglobulin binding domains are conserved in the genomes of these isolates but region X, the cell wall spanning domain of SpA, is a highly polymorphic sequence[114,115] (Box 1).

The immunosuppressive attributes of SpA have been ascribed to two distinct binding activities: association with the Fcγ domain and with the Fab domains of antibodies[116,117]. SpA binding to the Fcγ domain of IgG blocks phagocytosis of staphylococci[118], whereas SpA binding to Fab and crosslinking of V_H3 clan IgM promotes B cell superantigen activity[119](Fig. 4a). Of note, SpA binds specifically to V_H3 clan IgM antibodies, which mediate the predominant antibody responses to infection and immunization, but not to other clan antibodies. In the intravenous challenge model of *S. aureus* infected mice, *spa* expression suppresses antibody responses against many different staphylococcal antigens and provides antiphagocytic attributes, promoting staphylococcal survival in blood[120]. Infection of mice with *S. aureus spa* variants that cannot bind immunoglobulin is associated with attenuated disease and with antibody responses against many different antigens that can protect animals against subsequent lethal challenge with other *S. aureus* isolates[120].

Mice harbor a limited repertoire of V_H3^+ B cells, whereas humans possess large populations of V_H3^+ B cells, yet both species cannot develop SpA-neutralizing antibodies during infection[121]. *S. aureus* infection in humans triggers expansions of V_H3 idiotypic plasmablasts (>90% of blood plasmablasts), whose antibodies (B cell receptors) associate via their Fab domains with SpA but do not display pathogen specific binding activities[121]

(Fig. 4b). When mice are treated with purified SpA, crosslinking of V_H3 clonal B cells triggers proliferation and apoptotic collapse of expanded populations of B cells[122]. It is not clear, however, whether apoptotic collapse of expanded lymphocyte populations occurs during *S. aureus* infection in mice or in humans.

Non-toxigenic SpA, designated SpA_{KKAA}, was engineered by substituting twenty amino acid residues essential for its association with Ig Fcγ and Fab[123]. Although SpA_{KKAA} has twenty amino acid substitutions, this antigen elicits antibodies that neutralize SpA when injected into animals[123]. The SpA_{KKAA}-derived polyclonal antibodies promote phagocytosis of staphylococci and display adjuvant attributes by suppressing staphylococcal B cell superantigen activity and promoting humoral immune responses against a wide spectrum of antigens[123]. Studies with mouse monoclonal antibodies (SpA_{KKAA}-mAbs) corroborate this concept[53].

T cell responses

Staphylococcal T cell superantigens bind to MHC class II molecules on the surface of antigen-presenting cells, providing antigen independent crosslinking with T-cell receptors on T helper cells[124] (Fig. 4c). *S. aureus* strains have been shown to express 23 different enterotoxins and T cell superantigens[125]. Three superantigens are most frequently associated with human disease - toxic-shock-syndrome toxin 1 (TSST-1), staphylococcal enterotoxin B (SEB) and SEC - each providing high-affinity interactions with distinct subsets of Vβ chain T cell receptors[126]. In humans with toxic shock syndrome, *S. aureus* secretion of TSST-1 or other enterotoxins trigger expansions of cognate T cell populations, up to 30% of blood lymphocytes and non-specific release of cytokines, preventing a focused adaptive immune response[127].Depending on the site and severity of *S. aureus* infection/intoxication, superantigen-mediated activation of T cell responses may be associated with cytokine storms and toxic shock syndrome pathology[128]. Staphylococcal superantigens are also thought to interfere with antigen-specific proliferation of T cells and with antibody responses against specific subsets of staphylococcal antigens, including staphylococcal superantigens[129]. It is not yet known whether superantigens play a critical role in the suppression of T cell responses in mice that are observed during *S. aureus* bloodstream infections[130].

S. aureus can also manipulate T cell responses by promoting T cell lysis. For example, δ-toxin (Hld or δ-hemolysin), a member of the PSMα family, can lyse T cells[131] and has also been reported to trigger mast cell degranulation, which could be a key factor in the exacerbation of *S. aureus* infected atopic dermatitis lesions, where histamine release is otherwise triggered by antigen-induced crosslinking of IgE bound to FcεRI receptor[132]. Hld is encrypted within the *agr*-regulated RNA III molecule, the regulatory arm of staphylococcal quorum-sensing[133].

Outlook

S. aureus strains secrete a plethora of immune evasive molecules and, when placed under selective pressure, acquire mobile genetic elements with additional factors so that staphylococci meet the demands for invasion of host species and replication in specific

anatomical niches[13]. These strategies are accomplished through factors that block phagocyte chemotaxis, complement activation, phagocytic uptake and oxidative killing, often redirecting host defenses such as fibrin formation or NETosis to favour pathogen replication. Staphylococcal infection is also associated with perturbations of adaptive responses, including the disruptive proliferation of B and T cells, which prevents the establishment of protective immune responses. Why do *S. aureus* isolates acquire so many different immune evasion factors when other bacterial pathogens make do with only a small number? Addressing this question, one should consider that *S. aureus* maintains life-long association with its human hosts, colonizing and reiteratively invading large segments of the population. We know of no other bacterial pathogen able to sustain a similar lifestyle. Staphylococcal capabilities of causing recurrent and reiterative infections probably rely on two mechanisms. First, *S. aureus* manipulation of B and T cell responses must be successful, as increased age is not associated with decreased incidence. Second, mobile genetic elements enable acquisition and/or exchange of immune evasive traits between *S. aureus* strains and horizontal gene transfer may implement disease in individuals who did mount successful immune responses against immune evasion determinants. If pressed to predict the future of *S. aureus* as it evolves with a population whose lifespan continues to increase, we would forecast more invasion by mobile genetic elements and more immune evasion determinants.

Considering the formidable weapons of the pathogen against the host's immune defenses, development of vaccines against *S. aureus* is a daunting task. Conventional approaches for vaccine development follow the mantra of eliciting specific antibodies that trigger pathogen killing *in vitro* and disease protection in preclinical (animal) models of staphylococcal disease. The simplest means of achieving these goals are whole-cell vaccines, either killed or attenuated preparations. Indeed, autologous vaccines for individuals with recurrent *S. aureus* infection have been practised for many years[134]. This approach can elicit pathogen-specific antibodies; however, it has not been demonstrated to raise protective immunity[135]. Live-attenuated vaccines have been studied in animal models with variable success but not in humans. If one considers that the immune-evasive strategies are often species specific, it seems risky to derive claims on human protective immune responses against *S. aureus* from experiments with animals. What is true for whole-cell vaccines certainly applies to subunit vaccines. Antibodies against capsular polysaccharide, ClfA, IsdB and lipoteichoic acid bind to the surface of the pathogen, which enables phagocyte-mediated killing *in vitro* and provides protection from infection in specific animal models; however, the corresponding vaccines or antibodies did not achieve efficacy in clinical trials[136-138]. It occurred to us that *in vitro* assays for phagocytic killing of *S. aureus* often do not consider key evasion strategies of the pathogen and the corresponding defenses of humans. We believe this can be addressed with Lancefield's assay for antibody-mediated killing of bacteria in fresh anti-coagulated human blood[139]. The Lancefield assay can also be used for prospective studies in humans, assessing antibody titers, status of immunity (bactericidal activity of blood) and probability of disease. This approach may identify criteria for protective immunity, stratify patients at risk for *S. aureus* disease and guide applications for immune-therapy or vaccination that reduce the incidence of disease. Previous work targeted *S. aureus* B cell and T cell superantigens as vaccine antigens to enable the development of broad spectrum immune responses during each encounter of the host with this pathogen[123,140]. Another

promising approach exploited the structural relatedness of immune evasion factors to target multiple molecules with antibodies that recognize conserved structural features[141] (Box 2). Nonetheless, the efficacy of these approaches has not yet been assessed in human clinical trials.

Display items

Box 1

Variability of *Staphylococcus aureus* immune evasion determinants

Genome sequencing of *Staphylococcus aureus* isolates from humans and animals has provided insights into the origin, diversification and spread of the pathogen. Over the past 10,000 years, *S. aureus* evolved as colonizer and pathogen of humans and their lifestock[142], generating lineages with unique genetic traits and discrete host ranges[143]. Staphylococcal evolution was accompanied by the loss of genes encoding the CRISPR-cas system, which protect the genome against bacteriophage and mobile genetic elements. *S. aureus* relies on horizontal gene transfer mediated by these elements for adaptation, and preserves its identity through restriction modification systems and satellite phage-encoded pathogenicity islands that block bacteriophage replication[143]. When placed under selection in different hosts, *S. aureus* acquires mobile genetic elements that contain genes for antibiotic resistance, immune evasion and adhesion to specific anatomic niches. Analysis of large genome datasets described the core genome, which is common to all *S. aureus* isolates, and found that these core genes contribute to colonization, tissue invasion, establishment of abscess lesions, dissemination, immune evasion and the pathogenesis of reiterative disease[36]. Variable genes are associated with *S. aureus* colonization or invasion of specific host species or may be present in subsets of strains associated with increased virulence or specific disease, for example enterotoxin-mediated gastroenteritis[93]. As a rule of thumb, capsular polysaccharide and cell wall-anchored surface proteins are components of the core genome and contribute to immune evasion by synthesizing adenosine (adenosine synthase A), binding fibrinogen or fibrin (clumping factors A and B and fibronectin binding proteins A and B) and immunoglobulin (staphylococcal protein A). Several secreted proteins are components of the core genome: proteases cleaving host factors (aureolysin and staphopain), coagulases activating prothrombin (coagulase and von-Willebrand factor binding protein), toxins lysing immune cells (γ-hemolysin ABC and leukocidin AB), inhibitors of host proteases (staphylococcal extracellular adherence protein and its homologues) and phenol-soluble modulins, peptides that perturb host cell membranes and trigger neutrophil chemotaxis. Genetic determinants that interfere with neutrophil chemotaxis, phagocytosis, complement activation, promote lysis of immune cells or activate T lymphocytes often represent constituents of the variable genome. Table 1 summarizes core genome and variable immune evasion factors contributing to staphylococcal disease pathogenesis. Isolates of the CC75 lineage are predominantly found in the South-West Pacific and were originally isolated from superficial skin lesions of individuals from the indigenous communities of Australia[144]. CC75 strains lack the staphyloxanthin gene cluster, retain the CRISPR-cas system and lack pathogenicity islands (SaPIs), yet are endowed with

genomic islands α and β, a unique *coa* gene and a unique *spa* sequence type, which are elements important for staphylococcal evasion from innate and adaptive immune responses[144]. These strains, with the species designation *Staphylococcus argenteus*, may represent an early and terminal branch in the development of *S. aureus* in which mobile genetic elements were not incorporated into the genome because the retained CRISPR-cas system prevented horizontal gene transfer[144].

Box 2

Structural features of immune evasion factors

Crystallographic analysis of *S. aureus* immune evasion determinants revealed five discrete structural domains that enable specific interactions with the host's immune system: oligonucleotide-binding (OB) fold, β-grasp domain, triple-helical bundle (THB), β-pore forming toxin (β-PFT), and immunoglobulin-like fold (Ig). Varying the amino acid sequence for these domains has created panoplies of ligands that interact with the defence molecules of infected hosts at the places that matter most[4,145]. Thus, the study of *S. aureus* immune evasion factors laid bare the most intricate workings of the human immune system and identified new avenues for the therapy of autoimmune and inflammatory diseases. Examples for immune evasion factors with OB fold and β-grasp domains include the staphylococcal T cell superantigens (SEA, SEB, SEC1-3, SED, SEE, SEG, SHE, SEI, SEJ, SEK, SEL, SEM, SEN, SEO, SEP, SEQ, SER, SEU, TSST-1/2 and SelX) and the staphylococcal superantigen-like family (SSL1-13)[125]. CHIPS, FLIPr, FLIPr-L, Eap, EapH1, and EapH2 have β-grasp domains but not an OB fold[68,146]. Immune evasion factors with triple helical bundles include Ecb, Efb, SpA, Sbi, SCIN, SCIN-B and SCIN-C[147], whereas HlgABC, LukAB (LukGH), LukED, LukMF, PVL and Hla are members of the β-PFT family[79]. Surface proteins with IgG-like domains include the immune evasion factor ClfA and its relatives ClfB, FnBPA and FnBPB[102] (Table 1).

Acknowledgements

Biographies

Vilasack Thammavongsa was educated at the University of Michigan, Ann Arbor, where he received graduate training in immunology in the laboratory of Professor Malini Raghavan. He then undertook a postdoctoral fellowship in bacterial pathogenesis under the guidance of Professor Olaf Schneewind at the University of Chicago, studying the immune evasive properties of *Staphylococcus aureus*. He is currently a scientist at REGENERON Pharmaceuticals in the Department of Discovery Sciences (Target Information), developing new therapies for human diseases.

Hwan Keun Kim earned his Ph.D. in the Department of Microbiology at the University of Chicago. During doctoral training in the laboratory of Professor Olaf Schneewind, his thesis focused on identifying, characterizing and developing bacterial antigens into vaccines against *Staphylococcus aureus*. Hwan Keun Kim now investigates the immune-modulatory mechanisms of *S. aureus* in preclinical models for staphylococcal disease.

Dominique Missiakas was educated at the University of Montpellier, France and received a Ph.D. in enzymology from the University of Paris (Orsay), studying in the laboratory of Professor Jeannine Yon. Following fellowship training with Professor Costa Georgopoulos at the University of Utah (Salt Lake City, USA) and the University of Geneva, Switzerland, Dominique Missiakas worked at the CNRS in Marseille, France and was subsequently appointed Assistant Professor of Microbiology at the University of California, Los Angeles. In 2001, Dominique Missiakas moved to the University of Chicago, where she is currently Professor in the Department of Microbiology. Dominique Missiakas' laboratory studies staphylococcal agglutination and type VII secretion as well as S-layer assembly in *Bacillus anthracis*.

Olaf Schneewind was educated at the University of Cologne, Germany. Following postdoctoral fellowship at the Rockefeller University in the laboratory of Professor Vincent A. Fischetti, he joined the faculty at the University of California, Los Angeles. In 2001, Olaf Schneewind moved to the University of Chicago, where he founded the graduate program in Microbiology (Committee on Microbiology) and the Department of Microbiology. He is currently the Louis Block Professor and Chair of the Department of Microbiology. Olaf Schneewind's laboratory studies molecular mechanisms of disease pathogenesis for several microbes, including *Bacillus anthracis*, *Staphylococcus aureus* and *Yersinia pestis*.

Glossary

Recurrence	The propensity of *Staphylococcus aureus* infections to reoccur when surgery and/or antibiotic therapy are initially effective.
Abscess	The pathological product of *S. aureus* infection, harboring a staphylococcal abscess community within a pseudocapsule of fibrin deposits that is surrounded by layers of infiltrating immune cells destroying physiological organ tissue.
Anaphylatoxin	Protein fragments generated during complement activation of C3a and C5a that trigger immune responses via C3a and C5a receptors on immune cells.
Dabigatran	A small molecule that directly binds and inhibits thrombin as well as staphylothrombin, the complex formed between Coa or vWbp and prothrombin.
Fab domain	The portion of antibodies dedicated to antigen binding.
Fcγ domain	The portion of antibodies dedicated to C1q complement and Fc receptor activation.

Superantigen	Molecules that crosslink B cell receptors (IgM) or T cell receptors and major histocompatibility complexes to trigger lymphocyte proliferation, thereby diverting adaptive immune responses.
Plasmablast	Immature B cell in blood that secretes antibodies.
Enterotoxin	Staphylococcal superantigen that crosslinks MHC class II molecules and T-cell receptors, thereby triggering T cell proliferation, anergy and cytokine storms.
Autologous vaccine	A whole-cell killed *S. aureus* vaccine administered to an infected individual that was derived from the patient's isolate.
Opsonization	Deposition of complement components on bacterial surfaces to promote recognition, phagocytosis and killing by host phagocytes.
Fibrinogen	An abundant glycoprotein of vertebrates that, when cleaved by thrombin (factor IIa) or staphylothombin, self-assembles into fibrin clots.
V_H3 clan IgM	Immunoglobulin M derived from one of three clans of V_H genes whose products provide the scaffold for the antigen binding determinants of antibodies.
FcαRI	The immunoglobulin A Fc receptor, which regulates mucosal immune responses in humans.
Leukocidins	Bacterial secreted toxins targeting white blood cells (leukocytes) for destruction.
Factor Xa	The activated serine protease, also designated thrombokinase, which cleaves prothrombin to activate the clotting cascade of vertebrates.
Sortase	The bacterial transpeptidase responsible for anchoring surface proteins to the cell wall envelope.
Idiotype	A set of epitopes on the V region of an antibody molecule.
Fibronectin	High molecular weight glycoprotein of the extracellular matrix of vertebrates that associates with integrins on cell surfaces.
Core genome	The portion of the genome shared by all members of a bacterial species.

REFERENCES

1. van Belkum A, et al. Co-evolutionary aspects of human colonisation and infection by *Staphylococcus aureus*. Infect. Genet. Evol. 2009; 9:32–47. [PubMed: 19000784]

2. David MZ, Daum RS. Community-associated methicillin-resistant *Staphylococcus aureus*: epidemiology and clinical consequences of an emerging epidemic. Clin. Microbiol. Rev. 2010; 23:616–687. [PubMed: 20610826]

3. Kallen AJ, et al. Health care-associated invasive MRSA infections, 2005-2008. JAMA. 2010; 304:641–648. [PubMed: 20699455]

4. Spaan AN, Surewaard BGJ, Nijland R, van Strijp JAG. Neutrophils versus *Staphylococcus aureus*: a biological tug of war. Annu. Rev. Microbiol. 2013; 67:629–650. This excellent review summarizes the molecular events that occur during encounters between neutrophils and staphylococci. [PubMed: 23834243]

5. Curnutte JT, Whitten DM, Babior BM. Defective superoxide production by granulocytes from patients with chronic granulomatous disease. N. Engl. J. Med. 1974; 290:593–597. [PubMed: 4359964]

6. Casanova JL, Holland SM, Notarangelo LD. Inborn errors of human JAKs and STATs. Immunity. 2012; 36:515–528. [PubMed: 22520845]

7. Maródi L, et al. Molecular mechanisms of mucocutaneous immunity against *Candida* and *Staphylococcus* species. J. Allergy Clin. Immunol. 2012; 130:1019–1027. [PubMed: 23040277]

8. Chemaly RF, et al. Characteristics and outcomes of methicillin-resistant *Staphylococcus aureus* surgical-site infections in patients with cancer: a case-control study. Ann. Surg. Oncol. 2010; 17:1499–1506. [PubMed: 20127184]

9. Spaan AN, et al. The staphylococcal toxin panton-valentine leukocidin targets human c5a receptors. Cell Host Microbe. 2013; 13:584–594. This report describes the C5a receptor as the target of PVL, an important leukocidin secreted by some *S. aureus* strains. [PubMed: 23684309]

10. Williams RJ, et al. Identification of a novel gene cluster encoding staphylococcal exotoxin-like proteins: characterization of the prototypic gene and its protein product, SET1. Infect. Immun. 2000; 68:4407–4415. [PubMed: 10899837]

11. Fitzgerald JR, et al. Genome diversification in *Staphylococcus aureus*: molecular evolution of a highly variable chromosomal region encoding the staphylococcal exotoxin-like family of proteins. Infect. Immun. 2003; 71:2827–2838. [PubMed: 12704157]

12. Arcus VL, Langley R, Proft T, Fraser JD, Baker EN. The three-dimensional structure of a superantigen-like protein, SET3, from a pathogenicity island of the *Staphylococcus aureus* genome. J. Biol. Chem. 2002; 277:32274–32281. [PubMed: 12082105]

13. McCarty AJ, Lindsay JA. *Staphylococcus aureus* innate immune evasion is lineage-specific: a bioinformatics study. Infect. Genet. Evol. 2013; 19:7–14. This report characterizes lineage-specific alleles and distribution of *S. aureus* immune evasion determinants. [PubMed: 23792184]

14. Bestebroer J, et al. Staphylococcal superantigen-like 5 binds PSGL-1 and inhibits P-selectin-mediated neutrophil rolling. Blood. 2007; 109:2936–2943. [PubMed: 17132726]

15. Chung MC, et al. The crystal structure of staphylococcal superantigen-like protein 11 in complex with sialyl Lewis X reveals the mechanism for cell binding and immune inhibition. Mol. Microbiol. 2007; 66:1342–1355. [PubMed: 18045383]

16. Bestebroer J, et al. Staphylococcal SSL5 inhibits leukocyte activation by chemokines and anaphylatoxins. Blood. 2009; 113:328–337. [PubMed: 18941109]

17. de Haas CJ, et al. Staphylococcal superantigen-like 5 activates platelets and supports platelet adhesion under flow conditions, which involves glycoprotein Ibalpha and alpha IIb beta 3. J. Thromb. Haemost. 2009; 7:1867–1874. [PubMed: 19656281]

18. Hu H, et al. GPVI and GPIbα mediate staphylococcal superantigen-like protein 5 (SSL5) induced platelet activation and direct toward glycans as potential inhibitors. PLoS One. 2011; 6:e19190. [PubMed: 21552524]

19. Armstrong PC, et al. Staphylococcal superantigen-like protein 5 induces thrombotic and bleeding complications *in vivo*: inhibition by an anti-SSL5 antibody and the glycan bimosiamose. J. Thromb. Haemost. 2012; 10:2607–2609. [PubMed: 23039170]

20. Itoh S, et al. Staphylococcal superantigen-like protein 5 inhibits matrix metalloproteinase 9 from human neutrophils. Infect. Immun. 2010; 78:3298–3305. [PubMed: 20479083]

21. Hermans SJ, et al. Structural and functional properties of staphylococcal superantigen-like protein 4. Infect. Immun. 2012; 80:4004–4013. [PubMed: 22949551]

22. Yokoyama R, et al. Staphylococcal superantigen-like protein 3 binds to the Toll-like receptor 2 extracellular domain and inhibits cytokine production induced by *Staphylococcus aureus*, cell wall component, or lipopeptides in murine macrophages. Infect. Immun. 2012; 80:2816–2825. [PubMed: 22665377]

Thammavongsa et al. Page 18

23. Fevre C, et al. *Staphylococcus aureus* proteins SSL6 and SElX interact with neutrophil receptors as identified using secretome phage display. Cell. Microbiol. 2014; 16:1646–1665. [PubMed: 24840181]

24. Chavakis T, et al. Staphylococcus aureus extracellular adherence protein serves as anti-inflammatory factor by inhibiting the recruitment of host leukocytes. Nat. Med. 2002; 8:687–693. [PubMed: 12091905]

25. Peschel A, Otto M. Phenol-soluble modulins and staphylococcal infection. Nat. Rev. Microbiol. 2013; 11:667–673. [PubMed: 24018382]

26. Kretschmer D, et al. Human formyl peptide receptor 2 senses highly pathogenic *Staphylococcus aureus*. Cell Host Microbe. 2010; 7:463–473. This paper identifies formyl receptor 2 signalling as the target for *S. aureus* phenol-soluble modulins. [PubMed: 20542250]

27. Forsman H, Christenson K, Bylund J, Dahlgren C. Receptor-dependent and - independent immunomodulatory effects of phenol-soluble modulin peptides from *Staphylococcus aureus* on human neutrophils are abrogated through peptide inactivation by reactive oxygen species. Infect. Immun. 2012; 80:1987–1995. [PubMed: 22431645]

28. Cheung GY, et al. Production of an attenuated phenol-soluble modulin variant unique to the MRSA clonal complex 30 increases severity of bloodstream infection. PLoS Pathog. 2014; 10:e1004298. [PubMed: 25144687]

29. van Wamel WJ, Rooijakkers SH, Ruyken M, van Kessel KP, van Strijp JA. The innate immune modulators staphylococcal complement inhibitor and chemotaxis inhibitory protein of *Staphylococcus aureus* are located on b-hemolysin-converting bacteriophages. J. Bacteriol. 2006; 188:1310–1315. [PubMed: 16452413]

30. de Haas CJ, et al. Chemotaxis inhibitory protein of *Staphylococcus aureus*, a bacterial antiinflammatory agent. J. Exp. Med. 2004; 199:687–695. This report characterizes CHIPS as an inhbitor of chemotaxis and complement-mediated immune cell activation. [PubMed: 14993252]

31. Postma B, et al. Chemotaxis inhibitory protein of *Staphylococcus aureus* binds specifically to the C5a and formylated peptide receptor. J. Immunol. 2004; 172:6994–7001. [PubMed: 15153520]

32. Prat C, Bestebroer J, de Haas CJ, van Strijp JA, van Kessel KP. A new staphylococcal anti-inflammatory protein that antagonizes the formyl peptide receptor-like 1. J. Immunol. 2006; 177:8017–8026. [PubMed: 17114475]

33. Prat C, et al. A homolog of formyl peptide receptor-like 1 (FPRL1) inhibitor from *Staphylococcus aureus* (FPRL1 inhibitory protein) that inhibits FPRL1 and FPR. J. Immunol. 2009; 183:6569–6578. [PubMed: 19846866]

34. Laarman AJ, et al. *Staphylococcus aureus* staphopain A inhibits CXCR2-dependent neutrophil activation and chemotaxis. EMBO J. 2012; 31:3607–3619. [PubMed: 22850671]

35. Bubeck Wardenburg J, Williams WA, Missiakas D. Host defenses against *Staphylococcus aureus* infection require recognition of bacterial lipoproteins. Proc. Nat. Acad. Sci. USA. 2006; 103:13831–13836. [PubMed: 16954184]

36. Cheng AG, et al. Genetic requirements for *Staphylococcus aureus* abscess formation and persistence in host tissues. FASEB J. 2009; 23:3393–3404. [PubMed: 19525403]

37. Gros P, Milder FJ, Janssen BJ. Complement driven by conformational changes. Nat. Rev. Immunol. 2008; 8:48–58. [PubMed: 18064050]

38. Laarman A, Milder F, van Strijp JA, Rooijakkers SH. Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications. J. Mol. Med. 2010; 88:115–120. [PubMed: 20062962]

39. O'Riordan K, Lee JC. Staphylococcus aureus capsular polysaccharides. Clin. Microbiol. Rev. 2004; 17:218–234. [PubMed: 14726462]

40. Montgomery CP, et al. Comparison of virulence in community-associated methicillin-resistant *Staphylococcus aureus* pulsotypes USA300 and USA400 in a rat model of pneumonia. J. Infect. Dis. 2008; 198:561–570. [PubMed: 18598194]

41. Laarman AJ, et al. *Staphylococcus aureus* metalloprotease aureolysin cleaves complement C3 to mediate immune evasion. J. Immunol. 2011; 186:6445–6453. [PubMed: 21502375]

42. Rooijakkers SH, et al. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat. Immunol. 2005; 6:920–927. The paper discovers SCIN as an inhibitor of C3 convertases, blocking C3b deposition on staphylococcal surfaces. [PubMed: 16086019]

43. Jongerius I, et al. Staphylococcal complement evasion by various convertase-blocking molecules. J. Exp. Med. 2007; 204:2461–2471. This manuscript identifies SCIN-B, SCIN-C, Ecb and Efb as inhibitors of C3 and C5 convertases. [PubMed: 17893203]

44. Chen H, et al. Allosteric inhibition of complement function by a staphylococcal immune evasion protein. Proc. Natl. Acad. Sci. USA. 2010; 107

45. Amdahl H, et al. Staphylococcal Ecb protein and host complement regulator factor H enhance functions of each other in bacterial immune evasion. J. Immunol. 2013; 191:1775–1184. [PubMed: 23863906]

46. Jongerius I, Garcia BL, Geisbrecht BV, van Strijp JA, Rooijakkers SH. Convertase inhibitory properties of staphylococcal extracellular complement-binding protein. J. Biol. Chem. 2010; 285:14973–14979. [PubMed: 20304920]

47. Ko YP, et al. Phagocytosis escape by a *Staphylococcus aureus* protein that connects complement and coagulation proteins at the bacterial surface. PLoS Pathog. 2013; 9:e1003816. [PubMed: 24348255]

48. Jongerius I, et al. *Staphylococcus aureus* virulence is enhanced by secreted factors that block innate immune defenses. J. Innate Immun. 2012; 4:301–311. [PubMed: 22327617]

49. Bestebroer J, et al. Functional basis for complement evasion by staphylococcal superantigen-like 7. Cell Microbiol. 2010; 12:1506–1516. [PubMed: 20545943]

50. Patel D, Wines BD, Langley RJ, Fraser JD. Specificity of staphylococcal superantigen-like protein 10 toward human IgG1 Fc domain. J. Immunol. 2010; 184:6283–6292. [PubMed: 20427768]

51. Itoh S, et al. Staphylococcal superantigen-like protein 10 (SSL10) inhibits blood coagulation by binding to prothrombin and factor Xa via their γ-carboxyglutamic acid (Gla) domain. J. Biol. Chem. 2013; 288:21569–21580. [PubMed: 23754290]

52. Zhang L, Jacobsson K, Vasi J, Lindberg M, Frykberg L. A second IgG-binding protein in *Staphylococcus aureus*. Microbiology. 1998; 144:985–991. [PubMed: 9579072]

53. Kim HK, et al. Protein A-specific monoclonal antibodies and the prevention of *Staphylococcus aureus* disease in mice. Infect. Immun. 2012; 80:3460–3470. [PubMed: 22825452]

54. Burman JD, et al. Interaction of human complement with Sbi, a staphylococcal immunoglobulin-binding protein: indications of a novel mechanism of complement evasion by *Staphylococcus aureus*. J. Biol. Chem. 2008; 283:17579–17593. [PubMed: 18434316]

55. Haupt K, et al. The *Staphylococcus aureus* protein Sbi acts as a complement inhibitor and forms a tripartite complex with host complement Factor H and C3b. PLoS Pathog. 2008; 4:e1000250. The manuscript explains the functional properties of Sbi-mediated immune evasion. [PubMed: 19112495]

56. Parry MA, et al. The ternary microplasmin-staphylokinase-microplasmin complex is a proteinase-cofactor-substrate complex in action. Nat. Struct. Biol. 1998; 5:917–923. [PubMed: 9783753]

57. Rooijakkers SH, van Wamel WJ, Ruyken M, van Kessel KP, van Strijp JA. Anti-opsonic properties of staphylokinase. Microbes Infect. 2005; 7:476–484. [PubMed: 15792635]

58. Jin T, et al. *Staphylococcus aureus* resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J. Immunol. 2004; 172:1169–1176. [PubMed: 14707093]

59. Kang M, et al. Collagen-binding microbial surface components recognizing adhesive matrix molecule (MSCRAMM) of Gram-positive bacteria inhibit complement activation via the classical pathway. J. Biol. Chem. 2013; 288:20520–20531. [PubMed: 23720782]

60. Bera A, Herbert S, Jakob A, Vollmer W, Götz F. Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan *O*-acetyltransferase OatA is the major determinant for lysozyme resistance of *Staphylococcus aureus*. Mol. Microbiol. 2005; 55:778–787. [PubMed: 15661003]

61. Peschel A, et al. Inactivation of the *dlt* operon in *Staphylococcus aureus* confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J. Biol. Chem. 1999; 274:8405–8410. [PubMed: 10085071]

62. Ernst CM, Peschel A. Broad-spectrum antimicrobial peptide resistance by MprF-mediated aminoacylation and flipping of phospholipids. Mol. Microbiol. 2011; 80:290–299. [PubMed: 21306448]

63. Pelz A, et al. Structure and biosynthesis of staphyloxanthin from *Staphylococcus aureus*. J. Biol. Chem. 2005; 280:32493–32498. [PubMed: 16020541]

64. Liu GY, et al. *Staphylococcus aureus* golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J. Exp. Med. 2005; 202:209–215. [PubMed: 16009720]

65. Karavolos MH, Horsburgh MJ, Ingham E, Foster SJ. Role and regulation of the superoxide dismutases of *Staphylococcus aureus*. Microbiology. 2003; 149:2749–2758. [PubMed: 14523108]

66. Cosgrove K, et al. Catalase (KatA) and alkyl hydroperoxide reductase (AhpC) have compensatory roles in peroxide stress resistance and are required for survival, persistence, and nasal colonization in *Staphylococcus aureus*. J. Bacteriol. 2007; 189:1025–1035. [PubMed: 17114262]

67. Richardson AR, Libby SJ, Fang FC. A nitric oxide-inducible lactate dehydrogenase enables *Staphylococcus aureus* to resist innate immunity. Science. 2008; 319:1672–1676. A report on how staphylococcal metabolism diverts nitrosative stress and provides escape from phagocytic killing. [PubMed: 18356528]

68. Stapels DA, et al. *Staphylococcus aureus* secretes a unique class of neutrophil serine protease inhibitors. Proc. Natl. Acad. Sci. USA. 2014; 111:13187–13192. Three secreted molecules of *S. aureus* - Eap, EapH1 and EapH2 - block proteases of neutrophils to escape phagocytic killing. [PubMed: 25161283]

69. Wang R, et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat. Med. 2007; 13:1418–1420. [PubMed: 18064034]

70. Surewaard BG, et al. Staphylococcal alpha-phenol soluble modulins contribute to neutrophil lysis after phagocytosis. Cell. Microbiol. 2013; 15:1427–1437. [PubMed: 23470014]

71. Heuck AP, Tweten RK, Johnson AE. Beta-barrel pore-forming toxins: intriguing dimorphic proteins. Biochemistry. 2001; 40:9065–9073. [PubMed: 11478872]

72. DeLeo FR, et al. Molecular differentiation of historic phage-type 80/81 and contemporary epidemic *Staphylococcus aureus*. Proc. Natl. Acad. Sci. USA. 2011; 108:18091–18096. [PubMed: 22025717]

73. Wilke GA, Bubeck Wardenburg J. Role of a disintegrin and metalloprotease 10 in *Staphylococcus aureus* alpha-hemolysin-mediated cellular injury. Proc. Natl. Acad. Sci. USA. 2010; 107:13473–13478. The paper identifies ADAM10 as the receptor for staphylococcal α-hemolysin. [PubMed: 20624979]

74. Becker RE, Berube BJ, Sampedro GR, Dedent AC, Bubeck Wardenburg J. Tissue-specific patterning of host innate immune responses by *Staphylococcus aureus* α-toxin. J. Innate Immun. 2014; 6:619–631. [PubMed: 24820433]

75. Bubeck Wardenburg J, Schneewind O. Vaccine protection against *Staphylococcus aureus* pneumonia. J. Exp. Med. 2008; 205:287–294. [PubMed: 18268041]

76. Bubeck Wardenburg J, Palazzolo-Ballance AM, Otto M, Schneewind O, DeLeo FR. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant *Staphylococcus aureus* disease. J. Infect. Dis. 2008; 198:1166–1170. [PubMed: 18729780]

77. Powers ME, Kim HK, Wang Y-T, Bubeck-Wardenburg J. ADAM10 mediates vascular injury induced by *Staphylococcus aureus* α-hemolysin. J. Infect. Dis. 2012; 206

78. Miles G, Movileanu L, Bayley H. Subunit composition of a bicomponent toxin: staphylococcal leukocidin forms an octameric transmembrane pore. Protein Sci. 2002; 11:894–902. [PubMed: 11910032]

79. Alonzo, F. r.; Torres, VJ. The bicomponent pore-forming leucocidins of *Staphylococcus aureus*. Microbiol. Mol. Biol. Rev. 2014; 78:199–230. [PubMed: 24847020]

80. DuMont AL, et al. *Staphylococcus aureus* LukAB cytotoxin kills human neutrophils by targeting the CD11b subunit of the integrin Mac-1. Proc. Natl. Acad. Sci. USA. 2013; 110:10794–10799. [PubMed: 23754403]

81. Malachowa N, Kobayashi SD, Freedman B, Dorward DW, DeLeo FR. *Staphylococcus aureus* leukotoxin GH promotes formation of neutrophil extracellular traps. J. Immunol. 2013; 191:6022–6029. [PubMed: 24190656]

82. DuMont AL, et al. *Staphylococcus aureus* elaborates leukocidin AB to mediate escape from within human neutrophils. Infect. Immun. 2013; 81:1830–1841. [PubMed: 23509138]

83. Malachowa N, DeLeo FR. Staphylococcus aureus survival in human blood. Virulence. 2011; 2:567–569. This manuscript identifies the receptors for staphylococcal γ-hemolysins AB and CB on immune cells. [PubMed: 21971187]

84. Spaan AN, et al. he staphylococcal toxins γ-haemolysin AB and CB differentially target phagocytes by employing specific chemokine receptors. Nat. Commun. 2014; 5:5438. [PubMed: 25384670]

85. Malachowa N, et al. Global changes in *Staphylococcus aureus* gene expression in human blood. PLoS One. 2011

86. Malachowa N, et al. *Staphylococcus aureus* leukotoxin GH promotes inflammation. J. Infect. Dis. 2012; 206:1185–1193. [PubMed: 22872735]

87. Alonzo, F. r., et al. CCR5 is a receptor for *Staphylococcus aureus* leukotoxin ED. Nature. 2013; 493:51–55. This paper implicated G-protein coupled receptors as the targets of leukocidins, β-PFTs that are secereted by *S. aureus* to subvert innate immune responses. [PubMed: 23235831]

88. Reyes-Robles T, et al. *Staphylococcus aureus* leukotoxin ED targets the chemokine receptors CXCR1 and CXCR2 to kill leukocytes and promote infection. Cell Host Microbe. 2013; 14:453–459. [PubMed: 24139401]

89. Alonzo, F. r., et al. *Staphylococcus aureus* leucocidin ED contributes to systemic infection by targeting neutrophils and promoting bacterial growth *in vivo*. Mol. Microbiol. 2012; 83:423–435. [PubMed: 22142035]

90. Panton PN, Valentine FCO. Staphylococcal toxin. Lancet. 1932; 222:506–508.

91. Gillet Y, et al. Association between *Staphylococcus aureus* strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet. 2002; 359:753–759. [PubMed: 11888586]

92. Diep BA, et al. Polymorphonuclear leukocytes mediate *Staphylococcus aureus* Panton-Valentine leukocidin-induced lung inflammation and injury. Proc. Natl. Acad. Sci. USA. 2010; 107:5587–5592. [PubMed: 20231457]

93. McCarthy AJ, Lindsay JA. Genetic variation in *Staphylococcus aureus* surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions. BMC Microbiology. 2010; 10:173. [PubMed: 20550675]

94. Friedrich R, et al. Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. Nature. 2003; 425:535–539. This paper describes the molecular mechanism for staphylothrombin formation and activity. [PubMed: 14523451]

95. Panizzi P, et al. Fibrinogen substrate recognition by staphylocoagulase (pro)thrombin complexes. J. Biol. Chem. 2006; 281:1179–1187. [PubMed: 16230339]

96. McAdow M, et al. Preventing *Staphylococcus aureus* sepsis through the inhibition of its agglutination in blood. PLoS Pathog. 2011; 7:e1002307. [PubMed: 22028651]

97. Cheng AG, et al. Contribution of coagulases towards *Staphylococcus aureus* disease and protective immunity. PLoS Pathog. 2010; 6:e1001036. This paper reports that Coa and vWbp are key virulence factors for *S. aureus* abscess pathogenesis. [PubMed: 20700445]

98. McAdow M, et al. Coagulases as determinants of protective immune responses against *Staphylococcus aureus*. Infect. Immun. 2012; 80:3389–3398. [PubMed: 22825443]

99. Guggenberger C, Wolz C, Morrissey JA, Heesemann J. Two distinct coagulase-dependent barriers protect *Staphylococcus aureus* from neutrophils in a three dimensional *in vitro* infection model. PLoS Pathog. 2012; 8:e1002434. [PubMed: 22253592]

100. Ganesh VK, et al. A structural model of the *Staphylococcus aureus* ClfA-fibrinogen interaction opens new avenues for the design of anti-staphylococcal therapeutics. PLoS Pathog. 2008; 4:e1000226. [PubMed: 19043557]

101. Thomer L, et al. *N*-acetylglucosaminylation of serine-aspartate repeat proteins promotes *Staphylococcus aureus* blood stream infection. J. Biol. Chem. 2014; 289:3478–3486. [PubMed: 24344128]

102. Foster TJ, Geoghegan JA, Ganesh VK, Höök M. Adhesion, invasion and evasion: the many functions of the surface proteins of *Staphylococcus aureus*. Nat. Rev. Microbiol. 2014; 12:49–62. [PubMed: 24336184]

103. Edwards AM, Potts JR, Josefsson E, Massey RC. *Staphylococcus aureus* host cell invasion and virulence in sepsis is facilitated by the multiple repeats within FnBPA. PLoS Pathog. 2010; 6:e1000964. [PubMed: 20585570]

104. Heilmann C, et al. *Staphylococcus aureus* fibronectin-binding protein (FnBP)-mediated adherence to platelets, and aggregation of platelets induced by FnBPA but not by FnBPB. J. Infect. Dis. 2004; 190:321–329. [PubMed: 15216468]

105. Fitzgerald JR, et al. Fibronectin-binding proteins of *Staphylococcus aureus* mediate activation of human platelets via fibrinogen and fibronectin bridges to integrin GPIIb/IIIa and IgG binding to the FcgammaRIIa receptor. Mol. Microbiol. 2006; 59:212–230. [PubMed: 16359330]

106. Burke FM, McCormack N, Rindi S, Speziale P, Foster TJ. Fibronectin-binding protein B variation in *Staphylococcus aureus*. BMC Microbiol. 2010; 10:160. [PubMed: 20515471]

107. Panther E, et al. Expression and function of adenosine receptors in human dendritic cells. FASEB J. 2001; 15:1963–1970. [PubMed: 11532976]

108. Csóka B, et al. A2A adenosine receptors and C/EBPbeta are crucially required for IL-10 production by macrophages exposed to *Escherichia coli*. Blood. 2007; 110:2685–2695. [PubMed: 17525287]

109. Thammavongsa V, Kern JW, Missiakas DM, Schneewind O. *Staphylococcus aureus* synthesizes adenosine to escape host immune responses. J. Exp. Med. 2009; 206:2417–2427. The paper describes staphylococcal adenosine synthesis as an immune evasion mechanism. [PubMed: 19808256]

110. Berends ET, et al. Nuclease expression by *Staphylococcus aureus* facilitates escape from neutrophil extracellular traps. J. Innate Immun. 2010; 2:576–586. [PubMed: 20829609]

111. Thammavongsa V, Missiakas DM, Schneewind O. *Staphylococcus aureus* conversion of neutrophil extracellular traps into deoxyadenosine promotes immune cell death. Science. 2013; 342:863–866. This manuscript reports that *S. aureus* nuclease and AdsA degrade neutrophil NETs to produce deoxyadenosine and kill macrophages. [PubMed: 24233725]

112. Forsgren A, Nordström K. Protein A from *Staphylococcus aureus*: the biological significance of its interaction with IgG. Ann. N. Y. Acad. Sci. 1974; 236:252–266. [PubMed: 4278611]

113. Becker S, Frankel MB, Schneewind O, Missiakas DM. Release of protein A from the cell wall envelope of *Staphylococcus aureus*. Proc. Natl. Acad. Sci. USA. 2014; 111:1574–1579. [PubMed: 24434550]

114. Votintseva AA, et al. Prevalence of *Staphylococcus aureus* protein A (*spa*) mutants in the community and hospitals in Oxfordshire. BMC Microbiol. 2014; 14:63. [PubMed: 24621342]

115. Shopsin B, et al. Evaluation of protein A gene polymorphic region DNA sequencing for typing of *Staphylococcus aureus* strains. J. Clin. Microbiol. 1999; 37:3556–3563. [PubMed: 10523551]

116. Forsgren A, Sjöquist J. Protein A from *S. aureus*. I. Pseudo-immune reaction with human gamma-globulin. J. Immunol. 1966; 97:822–827. [PubMed: 4163007]

117. Sasso EH, Silverman GJ, Mannik M. Human IgM molecules that bind staphylococcal protein A contain VHIII H chains. J. Immunol. 1989; 142:2778–2783. [PubMed: 2495325]

118. Forsgren A, Quie PG. Effects of staphylococcal protein A on heat labile opsonins. J. Immunol. 1974; 112:1177–1180. [PubMed: 4590699]

119. Goodyear CS, Silverman GJ. Death by a B cell superantigen: In vivo VH-targeted apoptotic supraclonal B cell deletion by a staphylococcal toxin. J. Exp. Med. 2003; 197:1125–1139. [PubMed: 12719481]

120. Falugi F, Kim HK, Missiakas DM, Schneewind O. The role of protein A in the evasion of host adaptive immune responses by *Staphylococcus* aureus mBio. 2013; 4:e00575–00513. [PubMed: 23982075]

121. Pauli NT, et al. *Staphylococcus aureus* infection induces protein A-mediated immune evasion in humans. J. Exp. Med. 2014; 211:2331–2339. The paper describes the expansion of V_H3 clonal plasmablast populations in humans with *S. aureus* infection. [PubMed: 25348152]

122. Goodyear CS, Silverman GJ. Staphylococcal toxin induced preferential and prolonged *in vivo* deletion of innate-like B lymphocytes. Proc. Natl. Acad. Sci. USA. 2004; 101:11392–11397. [PubMed: 15273292]

123. Kim HK, Cheng AG, Kim H-Y, Missiakas DM, Schneewind O. Non-toxigenic protein A vaccine for methicillin-resistant *Staphylococcus aureus* infections. J. Exp. Med. 2010; 207:1863–1870. The manuscript describes a vaccine that blocks protein A B cell superantigen activity to elicit protective immune responses during staphylococcal infection. [PubMed: 20713595]

124. Jardetzky TS, et al. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature. 1994; 368:711–718. [PubMed: 8152483]

125. Fraser JD, Proft T. The bacterial superantigen and superantigen-like proteins. Immunol. Rev. 2008; 225:226–243. [PubMed: 18837785]

126. Stach CS, Herrera A, Schlievert PM. Staphylococcal superantigens interact with multiple host receptors to cause serious diseases. Immunol. Res. 2014; 59:177–181. [PubMed: 24838262]

127. Choi Y, et al. Selective expansion of T cells expressing V beta 2 in toxic shock syndrome. J. Exp. Med. 1990; 172:981–984. [PubMed: 2117641]

128. Ferry T, et al. Analysis of superantigenic toxin Vbeta T-cell signatures produced during cases of staphylococcal toxic shock syndrome and septic shock. Clin. Microbiol. Infect. 2008; 14:546–554. [PubMed: 18373692]

129. MacDonald HR, Lees RK, Baschieri S, Herrmann T, Lussow AR. Peripheral T-cell reactivity to bacterial superantigens in vivo: the response/anergy paradox. Immunol. Rev. 1993; 133:105–117. [PubMed: 8225363]

130. Ziegler C, et al. The dynamics of T cells during persistent *Staphylococcus aureus* infection: from antigen-reactivity to in vivo anergy. EMBO Mol. Med. 2011; 3:652–666. [PubMed: 21887823]

131. Collins J, Buckling A, Massey RC. Identification of factors contributing to T-cell toxicity of *Staphylococcus aureus* clinical isolates. J. Clin. Microbiol. 2008; 46:2112–2114. [PubMed: 18417658]

132. Nakamura Y, et al. *Staphylococcus* δ-toxin promotes allergic skin disease by inducing mass cell degranulation. Nature. 2013; 503:397–401. [PubMed: 24172897]

133. Novick RP, Geisinger E. Quorum sensing in staphylococci. Annu. Rev. Genet. 2008; 42:541–564. [PubMed: 18713030]

134. Rogers DE, Melly MA. Speculation on the immunology of staphylococcal infections. Ann. N.Y. Acad. Sci. 1965; 128:274–284. [PubMed: 5323953]

135. Holtfreter S, et al. Antibody responses in furunculosis patients vaccinated with autologous formalin-killed *Staphylococcus aureus*. Eur. J. Clin. Microbiol. Infect. Dis. 2011; 30:707–717. [PubMed: 21509478]

136. Weisman LE, et al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics. 2011; 128:271–279. [PubMed: 21788224]

137. Fowler VG, et al. Effect of an investigational vaccine for preventing *Staphylococcus aureus* infections after cardiothoracic surgery: a randomized trial. JAMA. 2013; 309:1368–1378. [PubMed: 23549582]

138. Shinefield H, et al. Use of a *Staphylococcus aureus* conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 2002; 346:491–496. [PubMed: 11844850]

139. Lancefield R. Current knowledge of type-specific M antigens of group A streptococci. J. Immunol. 1962; 89:307–313. [PubMed: 14461914]

140. Lussow AR, MacDonald HR. Differential effects of superantigen-induced "anergy" on priming and effector stages of a T cell-dependent antibody response. Eur. J. Immunol. 1994; 24:445–449. This report identifies antibodies with broad neutralizing activity for *S. aureus* β-PFTs. [PubMed: 8299694]

141. Rouha H, et al. Five birds, one stone: neutralization of alpha-hemolysin and four bi-component leukocidins of *Staphylococcus aureus* with a single human monoclonal antibody. mAbs. 2015; 7:243–254. [PubMed: 25523282]

142. Fitzgerald JR. Livestock-associated *Staphylococcus aureus*: origin, evolution and public health threat. Trends Microbiol. 2012; 20:192–198. [PubMed: 22386364]

143. Lindsay JA. *Staphylococcus aureus* genomics and the impact of horizontal gene transfer. Int. J. Med. Microbiol. 2013; 304:103–109. [PubMed: 24439196]

144. Holt DC, et al. A very early-branching *Staphylococcus aureus* lineage lacking the carotenoid pigment staphyloxanthin. Genome Biol. Evol. 2011; 3:881–895. [PubMed: 21813488]

145. Baker HM, et al. Crystal structures of the staphylococcal toxin SSL5 in complex with sialyl Lewis X reveal a conserved binding site that shares common features with viral and bacterial sialic acid binding proteins. J. Mol. Biol. 2007; 374:1298–1308. [PubMed: 17996251]

146. Geisbrecht BV, Hamaoka BY, Perman B, Zemla A, Leahy DJ. The crystal structures of EAP domains from *Staphylococcus aureus* reveal an unexpected homology to bacterial superantigens. J. Biol. Chem. 2005; 280:17243–17250. [PubMed: 15691839]

147. Lambris JD, Ricklin D, Geisbrecht BV. Complement evasion by human pathogens. Nat. Rev. Microbiol. 2008; 6:132–142. [PubMed: 18197169]

Online summary

○ *Staphylococcus aureus* evades innate and adaptive immune responses to cause localized or systemic infections in humans. Because the development of protective immunity is prevented, *S. aureus* infections reoccur even with antibiotic or surgical therapy.

○ Genome sequencing of *S. aureus* isolates from humans or domesticated animals revealed that only some immune evasion genes are conserved among all strains. Even conserved genes display sequence polymorphisms, which presents a formidable challenge for the design of *S. aureus* vaccines. Panoplies of immune evasion factors endow staphylococcal strains with unique virulence attributes and with the ability for epidemic spread.

○ Mechanisms have been revealed whereby *S. aureus* secreted products interfere with neutrophil chemotaxis, complement activation, opsonization and phagocytic killing of bacteria. Immune evasion determinants can interact with host factors from humans, but not with counterparts from other vertebrates, which presents a challenge for animal model development.

○ Hallmark of *S. aureus* is the secretion of coagulases that associate with prothrombin to generate fibrin clots. Through the fibrinogen/fibrin binding attributes of staphylococcal surface proteins, the pathogen shields itself from host phagocytes, which is a prerequisite for abscess formation in infected tissues.

○ *S. aureus* AdsA generates adenosine from adenine nucleotides during infection, thereby suppressing innate and adaptive immune responses through adenosine receptor signalling. Staphylococcal AdsA and nuclease collaborate to covert neutrophil NETs, the released DNA of host neutrophils, into deoxyadenosine, thereby restricting macrophage access to *S. aureus* abscess lesions.

○ Staphylococcal protein A (SpA) crosslinks B cell receptors (IgM) and triggers proliferative expansion of V_H3 clonal B cells and the secretion of antibodies that fail to recognize *S. aureus* antigens. SpA blocks host antibody responses that are required for the establishment of protective immunity.

○ T cell superantigens (SAgs or enterotoxins) crosslink MHC class II molecules of antigen presenting cells with the T cell receptor of T lymphocytes, promoting lymphocyte proliferation, anergy and the release of cytokines (cytokine storm). SAgs vary between *S. aureus* strains and activate distinct subsets of Vβ chain T cell receptors, endowing staphylococcal isolates with unique T cell avoidance attributes.

Figure 1. *Staphylococcus aureus* interference with chemotaxis, complement and killing by phagocytes

(a) Neutrophil extravasation and chemotaxis is inhibited by *Staphylococcus aureus* through the secretion of staphylococcal superantigen-like (SSL) molecules. SSL3 inhibits Toll-like receptor heterodimers; SSL5, SSL11 and SElX inhibit PSGL-1 signalling; and SSL6 inhibits the G-protein coupled receptor CD47. Other secreted proteins include chemotaxis inhibitory protein of *S. aureus* (CHIPS), which inhibits the complement receptor C5aR and the formyl-peptide receptors 1 and 2 (FPR1/2); formyl peptide receptor-like 1 inhibitor (FLIPr) and FLIPr-like (FLIPr-L), which inhibit FPR1/2; and staphopain, which inhibits signalling from the chemokine receptor CXCR2. **(b)** Complement activation and phagocytosis of staphylococci are blocked through the secretion of inhibitory factors to interfere with opsonization. Cna blocks the association of complement factor C1q bound to immunoglobulin with complement receptor C1r; SpA and Sbi binding to immunoglobulin blocks its association with C1q; Sbi, SpA, SSL7 and SSL10 sequester immunoglobulins to block their abilitiy to promote complement activation; Sbi (when associated with the host factors C3d and fH) and SSL7 also inactivate the complement factors C3 and C5, respectively; Sak associates with plasminogen (PLG) and activates the zymogen to cleave complement factor C3b and immunoglobulin; Efb, Ecb, Eap and SCIN inhibit C3 convertases; and aureolysin cleaves the complement factor C3, which compromises opsonization because the cleavage product C3b is degraded by a complex of the host proteins factor I (fI) and co-factor H (fH). **(c)** *S. aureus* inhibits neutrophil-mediated killing of phagocytosed bacteria by expressing several enzymes and inhibitors. The adenosine-synthesizing enzyme AdsA enables the inhibition of granulation via adenosine receptor (AdoR) signalling; staphyloxanthin, superoxide dismutase (SodA/SodM), the catalase KatG and alkylhydroperoxide reductase (AhpC) are antioxidants that reduce oxidative stress caused by phagosomal reactive oxygen species (ROS) and H_2O_2 generation; aureolysin (Aur) cleaves antimicrobial peptides; DltA-D promote D-alanyl esterification of teichoic acids to protect staphylococci from antimicrobial peptides; MprF modifies phosphatidylglycerol with alanine or lysine, another mechanism to protect staphylococci against antimicrobial peptides; Ldh and Hmp inhibit nitrosative stress; Eap, EapH1 and

EapH2 inhibit neutrophil serine proteases; and OatA *O*-acetylates peptidoglycan, which prevents its lysozymal degradation. **(d)** Secreted β-barrel pore forming toxins (β-PFTs), bind specific receptors on immune cells to impair immune cell functions or promote cell lysis. These β-PFTs include LukED, which binds to neutrophils, T cells and macrophages; HlgAB, which binds to neutrophils, macrophages and red blood cells; HlgCB and PVL, which bind to neutrophils and macrophages; and LukAB and Hla, which bind to neutrophils. Phenol-soluble modulin α (PSMα), which is another factor secreted by *S. aureus* but not a β-PFT, can also lyse white blood cells.

Figure 2. *Staphylococcus aureus* agglutination with fibrin provides protection against phagocytes Physiological host defenses immobilize bacteria through the activation of the serine protease zymogens prothrombin (also known as factor II) and factor X (not shown). In the contact activation pathway, surface contact results in the autocleavage of prothrombin (also known as factor II), thereby generating thrombin (also known as factor IIa). The *Staphylococcus aureus* superantigen-like protein SSL10 inhibits prothrombin autoactivation, whereas the *S. aureus* coagulases Coa and vWbp convert prothrombin to staphylothrombin. Both thrombin and staphylothrombin cleave fibrinopeptides A and B from fibrinogen to generate fibrin, which self-assembles and polymerizes into cable structures that immobilize bacteria. Thrombin activation results in the activation of additional haemostasis factors that facilitate the simultaneous attraction of phagocytes to immobilized bacteria, which is thus inhibited by SSL10 secretion. However, staphylothrombin cleaves fibrinopeptides from fibrinogen without activation of other haemostasis factors and promotes fibrin polymer assembly on the staphylococcal surface, where it protects the bacterium from neutrophils and phagocytic clearance. Fibrin agglutination on the staphylococcal surface also involves the *S. aureus* surface proteins ClfA, FnbpB and FnbpB, which bind to the fibrinogen γ-chains.

A. Adenosine (Ado) signaling

Macrophage
AdoR$_{1/2A/2B/3}$

Superoxide burst ▼
MHC-II ▼
IL-12 ▼

Neutrophil
AdoR$_{1/2A/2B/3}$

AdsA

S. aureus

Ado

B cell
AdoR$_{2A}$

Tissue injury ATP ADP AMP

CD39

CD73

T cell
AdoR$_{2A/2B}$

B. deoxy-Adenosine (dAdo) signaling

Macrophage apoptosis

Procaspase-3 → Caspase-3

dAdo

AdsA

dAMP

Nuc

NETosis

NETs

Staphylococcal
Abscess
Community

Infiltrated PMNs

Figure 3. *Staphylococcus aureus* AdsA perturbs adenosine and deoxyadenosine signalling
(a) *Staphylococcus aureus* infection and its associated inflammatory damage promote the release of ATP, which is converted by adenosine synthase A (AdsA) into the immune suppressive signalling molecule adenosine (A). Adenosine inhibits activation of B cells, T cells, macrophages and dendritic cells via adenosine receptor (AdoR) signalling by acting on four different receptors (AdoR$_{1/2A/2B/3}$). Under physiological conditions, CD39 and CD73 generate adenosine signals to limit inflammatory responses; CD39 and CD73 are also responsible for the adenosine halo surrounding immune cells and for immune suppressive states involving regulatory T cells (T cells expressing the Foxp3[+] marker protein (not shown)). **(b)** *S. aureus* induced NETosis of infiltrating neutrophils leads to nuclease-mediated degradation of the DNA fibres that are the major components of neutrophil extracellular traps (NETs) and AdsA-mediated conversion of 5'-monophosphate-deoxyadenosine into deoxyadenosine, which promotes autocleavage of the apoptosis factor pro-capsase 3 to caspase 3. Caspase 3 induces macrophage death, thereby protecting *S. aureus* against professional phagocytes.

Figure 4. *Staphylococcus aureus* manipulates B and T cell responses
(a) *Staphylococcus aureus* releases SpA into host tissues, where it binds to and crosslinks V_H3 clan B cell receptors. In B1 cells, marginal zone (MZ) B cells and B2 cells, SpA crosslinking is associated with proliferative expansion and apoptotic collapse. The death of these cells impedes the development of adaptive immunity during *S. aureus* infections. **(b)** In V_H3 plasmablasts, SpA crosslinking promotes somatic hypermutation and class switching from IgM antibodies to IgG antibodies, followed by the secretion of antibodies that are not specific for the *S. aureus* antigen. **(c)** *S. aureus* secretes T cell superantigen (SAg), which crosslinks major-histocompatibility complex class II antigens (MHCII) on the surface of antigen-presenting cells and T-cell receptors (TCR) on the surface of helper T (T_H) cells, triggering T cell expansion and anergy and causing cytokine storms. As a result, T cells specific for *S. aureus* antigens are not produced.

Table 1

Staphylococcus aureus immune evasion determinants, their function and epidemiology

Name	Gene	Genome	Proposed Function	Target	Alleles[13]
Adenosine synthase	*adsA*	core	Immune suppression	Ado, dAdo synthesis	1
Aureolysin	*aur*	core	Zn-protease	C3 (h)	1
Capsule	*cpsA-N*	core	Phagocytosis inhibition	-	2
CHIPS	*chp*	IEC1 (var)	Chemotaxis inhibition	FPR1, C5aR	1
ClfA	*clfA*	core	Phagocytosis inhibition	γFg, cfI	1
ClfB	*clfB*	core	Adherence	αFg, Keratin 10, Loricrin	1
Cna	*cna*	variable	Collagen adhesion, C1q binding	C1q	1
Coagulase	*coa*	core	Phagocytosis inhibition	FIIa, Fg	14
δ-toxin	*hld*	core	Mast cell activation	not known	1
Eap	*eap*	core	Phagocytic killing inhibition	ICAM1, C4b, elastase, cathepsin G, proteinase 3	15
EapH1	*eapH1*	core	Phagocytic killing inhibition	elastase, cathepsin G, proteinase 3	1
EapH2	*eapH2*	core	Phagocytic killing inhibition	elastase, cathepsin G, proteinase 3	1
Enterotoxin B	*seb*	SaPI	T cell superantigen	Vβ TCR	1
Enterotoxin C	*sec*	SaPI	T cell superantigen	Vβ TCR	1
Enterotoxin like IX	*selX*	core	T cell superantigen	PSGL-1	17
Ecb	*ecb*	IEC2 (con)	Complement inhibition	C3d (h,m)	2
Efb	*efb*	IEC2 (var)	Complement inhibition	C3d, αMβ2 (h,m)	2
FLIPr	*flipr*	IEC2 (var)	Chemotaxis inhibition	FPR2	9
FLIPr-L	*flipr-l*	IEC2 (var)	Chemotaxis inhibition	FPR1, FPR2	9
FnBPA	*fnbpA*	core	Phagocytosis inhibition, invasion	γFg, FN	7
FnBPB	*fnbpB*	core	Invasion, adherence	αFg, FN	7
HlgAB	*hlgAB*	*sbi/hlg* (con)	Phagosome escape	CXCR1, CXCR2, CCR2	2/3
HlgCB	*hlgCB*	*sbi/hlg* (con)	Phagosome escape	C5aR, C5L2	3/3
LukAB (LukGH)	*lukAB*	*hlb/lukAB*	PMN lysis, NETosis activation	CD11b	1/1
LukED	*lukED*	GIβ (var)	PMN lysis	CCR5, CXCR1, CXCR2	1/1
LukMF'	*lukMF*	GIβ (var)	PMN lysis	not known	
PSMα1	*psmα1*	core	Chemotaxis, PMN lysis	FPR2	1
PSMα2	*psmα2*	core	Chemotaxis, PMN lysis	FPR2	1
PSMα3	*psmα3*	core	Chemotaxis, PMN lysis	FPR2	1
PSMα4	*psmα4*	core	Chemotaxis, PMN lysis	FPR2	1
PSMβ1	*psmβ1*	PSMb (con)	Chemotaxis, PMN lysis	FPR2	1
PSMβ1	*psmβ2*	PSMb (var)	Chemotaxis, PMN lysis	FPR2	1
Panton-Valentin leucocidin (PVL)	*lukFS*	PVL phage	PMN lysis	C5aR	1
Staphylokinase	*sak*	IEC1 (var)	Phagocytosis Inhibition	Plasminogen→Fn, C3, IgG	1

Name	Gene	Genome	Proposed Function	Target	Alleles[13]
Sbi	*sbi*	*sbi/hlg* (con)	Phagocytosis Inhibition	IgG Fcγ, C3, FH	4
SCIN	*scn*	IEC1 (var)	Complement inhibition	C3bBb (h)	none
SCIN-B	*scnB*	IEC2 (var)	Complement inhibition	C3bBb (h)	7
SCIN-C	*scnC*	IEC2 (var)	Complement inhibition	C3bBb (h)	7
SpA	*spa*	core	Phagocytosis inhibition, B cell superantigen	Ig Fcγ, Ig Fab (VH3)	Xr (SpA typing)
SSL3	*ssl3*	GIα(var)	TLR signalling inhbition	TLR2	13
SSL5	*ssl5*	GIα (var)	Chemotaxis/Platelet inhibition	PSGL-1, GPCRs, GPIbα, GPVI	5
SSL6	*ssl6*	GIα (var)	Chemotaxis inhibition	PSGL-1	2
SSL7	*ssl7*	GIα (var)	Phagocytosis inhibition	IgA, C5	4
SSL10	*ssl10*	GIα (var)	Phagocytosis inhibition	IgG (h), Fg, Fn, FIIa, FXa	4
SSL11	*ssl11*	GIα (con)	Chemotaxis inhibition	PSGL-1	10
Staphyopain	*scpA*	core	Chemotaxis inhibition	CXCR2	1
TSST1	*tst*	SaPI1	T cell superantigen	Vβ2 TCR, αMHC class II	2
vWbp	*vwb*	core	Phagocytosis inhibition	FIIa, Fg, FXIII, FN	2